With organic exits slowing and trillions in unrealized venture value, secondaries are emerging as a vital liquidity tool. In this conversation, Matt Russell, Investment Director at Vencap and head of the firm’s secondary strategy, explains why the market is still nascent compared to private equity, how pricing and quality drive returns, and why 2025 could mark a breakout year for venture secondaries.
As private equity adapts to a prolonged high-cost environment, investors are being forced to rethink how they source deals, create value, and deploy capital. Ahead of her appearance at 0100 Europe (April 21–23), we spoke with Geraldine O’Keeffe, Partner at EQT Healthcare Growth, about how one of Europe’s leading investment platforms is transiting today’s market dynamics—across healthcare, technology, and beyond.
